AMGEN logo

AMGEN 1AMGN

Market Closed
22 Nov, 15:30
XMIL XMIL
278. 65
+3.35
+1.22%
149.84B Market Cap
19.61 P/E Ratio
9% Div Yield
7 Volume
18.58 Eps
275.30
Previous Close
Day Range
278.65 278.65
Year Range
201.05 337.65

1AMGN Chart

AMGEN Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Robert A. Bradway CEO
XMIL Exchange
US0311621009 ISIN
United States Country
26,700 Employees
9 Dec 2024 Last Dividend
22 Nov 1999 Last Split
17 Jun 1983 IPO Date

Overview

Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.

Products and Services

  • Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
  • Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
  • Prolia - Addresses osteoporosis in postmenopausal women.
  • XGEVA - Prevents skeletal-related events.
  • Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
  • Nplate - Treats immune thrombocytopenia.
  • KYPROLIS - For relapsed or refractory multiple myeloma patients.
  • Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
  • EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
  • Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
  • BLINCYTO - For patients with acute lymphoblastic leukemia.
  • TEPEZZA - Treats thyroid eye disease.
  • KRYSTEXXA - Addresses chronic refractory gout.
  • Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.

Contact Information

Address: One Amgen Center Drive
Phone: 805 447 1000